AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02975843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
Description: single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)
Study NCT02700737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image-based simulation modelling
Description: The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as limited dataset).
Study NCT02700737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imaging parameters currently recommended by clinical practice guidelines
Description: The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset).
Study NCT02700737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging parameters currently recommended by clinical practice guidelines
Description: The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset).
Study NCT00185393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)
Description: treatment with 90 Yttrium-labeled anti CD 20 antibody
Study NCT00185393 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no treatment
Description: no treatment
Study NCT03363633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium tetradecyl sulfate
Description: Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins
Study NCT03363633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression
Description: 20-30 mmHg compression stockings
Study NCT03363633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression
Description: 20-30 mmHg compression stockings
Study NCT03591380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.
Study NCT03674151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nylon dressing
Description: Non-staining Silver Nylon dressing with a permanently plated metallic surface on split-skin grafted third-degree burn wound
Study NCT03674151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manuka-Honey
Description: Manuka-Honey dressing on split-skin grafted third-degree burn wound
Study NCT03674151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iod (PVP-Iod)
Description: Povidone-Iod (PVP-Iod) dressing on split-skin grafted third-degree burn wound
Study NCT03674151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: Hydrogel dressing on split-skin grafted third-degree burn wound
Study NCT01708980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six different strength training exercises
Description: Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.~The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
Study NCT01265459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml
Description: Durolane is an intraarticular hyaluronic acid preparation
Study NCT02816918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extraluminal use of Univent bronchial Blocker
Description: Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision
Study NCT02816918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innerluminal use Univent bronchial Blocker
Description: Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
Study NCT01935843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-HER-2
Study NCT01014117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Study NCT01014117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Study NCT01014117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
Study NCT04638491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin for injection
Description: On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection
Study NCT01874171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT01874171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT01775631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urelumab
Study NCT00664001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anti-oxidant supplementation
Description: Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.
Study NCT00664001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo for anti-oxidant supplementation
Description: Matched placebo for anti-oxidant supplementation
Study NCT02801019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-poly
Description: comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
Study NCT02801019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-poly
Description: comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
Study NCT02801019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ArComXL
Description: comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
Study NCT02801019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ArComXL
Description: comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
Study NCT00863213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Description: Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested.
Study NCT00863213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
Study NCT00448643 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal Brachytherapy
Description: High-Dose Rate \[HDR\] or Low-Dose Rate \[LDR\], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
Study NCT00448643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
Study NCT00448643 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Abdominal Radiation [WAR] Therapy
Description: Whole Abdominal Radiation Therapy, Dose Escalated \[2-Levels\]; 6 -8 hours after administration of Cisplatin chemotherapy
Study NCT00197548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins-vitamins B-complex, C, and E
Description: One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
Study NCT00197548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
Study NCT01090323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670
Description: Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
Study NCT01324037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic algorithm
Description: diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
Study NCT03162367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous epidermal cell suspension
Description: First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
Study NCT03162367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver sulfadiazine ointment
Description: the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
Study NCT01082549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/carboplatin
Description: i.v.
Study NCT01082549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin plus Iniparib
Description: i.v.
Study NCT00344487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
Study NCT00540410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)
Description: Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
Study NCT03781986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
Study NCT00540410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem® (arthemether+ lumefantrine)
Description: Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days
Study NCT02059291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
Study NCT02059291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to canakinumab solution for subcutaneous injection
Study NCT06275633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Medicine response
Study NCT01819532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Milking group
Description: The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord.
Study NCT01819532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate cord clamping
Description: The umbilical cord will be clamped and cut immediately after delivery of the neonate.
Study NCT02411864 — intervention group
Intervention type: OTHER
Intervention: different low b-values distribution
Study NCT01719744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Study NCT01433289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
Study NCT03781986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
Study NCT01433289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02902484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
Study NCT03680118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autogenous rings with GBR and autogenous graft with ti-mesh
Description: * Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~* Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~* Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~* The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures.
Study NCT02310334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Exercise Session
Description: Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.
Study NCT02310334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unguided Exercise Session
Description: Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
Study NCT01579851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: sugammadex~* 4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~* 2 mg/kg : if there is at least two responses to Train of Four stimulations
Study NCT00561548 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: rectosigmoïdal biopsies
Description: rectosigmoïdal biopsies
Study NCT03867318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin administered orally QD as 10 mg tablets.
Study NCT03867318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe administered orally QD as 10 mg tablets
Study NCT03867318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ezetimibe
Description: Single placebo tablet administered orally QD
Study NCT03867318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atorvastatin
Description: Single placebo tablet administered orally QD
Study NCT01383343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01383343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT01383343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT01383343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT01383343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT04117867 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patiens with intraoperative hypotension
Description: In this study, we will use four previously defined thresholds for intraoperative hypotension: two absolute thresholds (MAP less than 50 mmHg and MAP less than 60 mmHg) and two relative thresholds to the baseline MAP (a decrease of 30% or more and a decrease of 40% or more). A definition of baseline value most frequently reported was the arterial blood pressure before the induction of anesthesia. Therefore, the baseline MAP used in calculating the relative thresholds is defined as the mean MAP of all available blood pressure measurements before induction of anesthesia in the operating room.
Study NCT04412785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: • The initial dose will be 9 mg/kg/day oral divided q12h. For IV, the dose will be 3mg/kg/day by continuous IV infusion.
Study NCT02219867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Drug (including placebo)
Study NCT01161199 — intervention group
Intervention type: PROCEDURE
Intervention: Leukapheresis
Description: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
Study NCT02310867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.
Study NCT02310867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand transplant
Description: The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
Study NCT02246413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAINBOW Intervention Program
Description: Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
Study NCT01649089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conization
Description: Undergo cone biopsy
Study NCT01649089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01649089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01649089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo hysterectomy